Human Secreted Proteins

Abstract

The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions (such as immune, cardiovascular, cancer, and other proliferative diseases, disorders, and/or conditions) related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

What is claimed is: 
     
         1 . A nucleic acid molecule comprising a polynucleotide sequence selected from the group consisting of:
 (a) a polynucleotide fragment of SEQ ID NO:X as referenced in Table 1A;   (b) a polynucleotide encoding a full length polypeptide of SEQ ID NO:Y or a full length polypeptide encoded by the cDNA Clone ID in ATCC Deposit No:Z corresponding to SEQ ID NO:Y as referenced in Table 1A;   (c) a polynucleotide encoding a predicted secreted form of SEQ ID NO:Y or a secreted form of the polypeptide encoded by the cDNA Clone ID in ATCC Deposit No:Z corresponding to SEQ ID NO:Y as referenced in Table 1A;   (d) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA Clone ID in ATCC Deposit No:Z corresponding to SEQ ID NO:Y as referenced in Table 1A;   (e) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA Clone ID in ATCC Deposit No:Z corresponding to SEQ ID NO:Y as referenced in Table 1A, wherein said fragment has biological activity;   (f) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y as referenced in Table 1B.1;   (g) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y as referenced in Table 2;   (h) a polynucleotide encoding a predicted epitope of SEQ ID NO:Y as referenced in Table 1B.1; and   (i) a polynucleotide which is at least 95% identical to a polynucleotide as defined in any one of (a)-(h).   
     
     
         2 . The nucleic acid molecule of  claim 1 , wherein said nucleic acid molecule comprises a heterologous polynucleotide sequence. 
     
     
         3 . A recombinant vector comprising the nucleic acid molecule of  claim 1 . 
     
     
         4 . A recombinant vector comprising the nucleic acid molecule of  claim 2 . 
     
     
         5 . A recombinant host cell comprising the recombinant vector of  claim 3 . 
     
     
         6 . A recombinant host cell comprising the recombinant vector of  claim 4 . 
     
     
         7 . Use of the nucleic acid molecule of  claim 1  for the preparation of a diagnostic or pharmaceutical composition for diagnosing or treating a medical condition. 
     
     
         8 . A polypeptide comprising an amino acid sequence selected from the group consisting of:
 (a) a full length polypeptide of SEQ ID NO:Y or a full length polypeptide encoded by the cDNA Clone ID in ATCC Deposit No:Z corresponding to SEQ ID NO:Y as referenced in Table 1A;   (b) a predicted secreted form of SEQ ID NO:Y or a secreted form of the polypeptide encoded by the cDNA Clone ID in ATCC Deposit No:Z corresponding to SEQ ID NO:Y as referenced in Table 1A;   (c) a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA Clone ID in ATCC Deposit No:Z corresponding to SEQ ID NO:Y as referenced in Table 1A;   (d) a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA Clone ID in ATCC Deposit No:Z corresponding to SEQ ID NO:Y as referenced in Table 1A, wherein said fragment has biological activity;   (e) a polypeptide domain of SEQ ID NO:Y as referenced in Table 1B.1;   (f) a polypeptide domain of SEQ ID NO:Y as referenced in Table 2;   (g) a predicted epitope of SEQ ID NO:Y as referenced in Table 1B.1; and   (h) a polypeptide which is at least 95% identical to a polypeptide as defined in any one of (a)-(g).   
     
     
         9 . The polypeptide of  claim 8 , wherein said polypeptide comprises a heterologous amino acid sequence. 
     
     
         10 . Use of the polypeptide of  claim 8  for identifying a binding partner comprising:
 (a) contacting the polypeptide of  claim 8  with a binding partner; and 
 (b) determining whether the binding partner increases or decreases activity of the polypeptide. 
 
     
     
         11 . Use of the polypeptide of  claim 8  for the preparation of a diagnostic or pharmaceutical composition for diagnosing or treating a medical condition. 
     
     
         12 . An antibody or fragment thereof that specifically binds the polypeptide of  claim 8 . 
     
     
         13 . Use of the antibody or fragment thereof of  claim 11  for the preparation of a diagnostic or pharmaceutical composition for diagnosing or treating a medical condition. 
     
     
         14 . Use of an agonist or antagonist of the polypeptide of  claim 8  for the preparation of a pharmaceutical composition for treating a medical condition.